Floatz logo

Vandazole

Rectum Adenocarcinoma

AC Camargo Cancer CenterSmall moleculePhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
73/ 100

Competitive context

39 Active assets in the Rectum Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Fluorouracilum
Merck Sharp & Dohme LLC
Phase 3BBB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BBB
Xaliplatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Cetuximab
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Pertuzumab
SWOG Cancer Research Network
Phase 2BB

View all 50 →

Same molecule, other indications

Vandazole is also rated in:

colorectal neoplasmActive
BB
Indicative · Phase 4
69 / 100
View asset →
rectal carcinomaActive
B
Indicative · Phase 4
63 / 100
View asset →
colorectal cancerActive
B
Indicative · Phase 4
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →